Compare Quest Diagnostics Inc (DGX) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NetFlix Inc — how do they compare? Quest Diagnostics Inc trades at $204 (market cap $22.80B), while NetFlix Inc trades at $73.61 (market cap $309.62B). The key difference: NetFlix Inc is far larger — about 13.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| DGX | NFLX | |
|---|---|---|
Market Cap | $22.80B | $309.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $127.42 |
52-Week Low | $166.42 | $70.91 |
Enterprise Value | $28.82B | $311.69B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Netflix (NFLX) trades at $73.83, showing modest daily gains of 0.63% but remains in a technical bearish trend. The stock demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $1.23 versus $0.763 expected, while revenue growth accelerated to 16% year-over-year. Analyst sentiment remains predominantly bullish with 66% buy ratings, though technical indicators signal near-term caution with the stock approaching key support levels.
The investment outlook balances robust fundamentals against technical headwinds. Netflix's expanding advertising business and projected $3 billion in ad revenue by 2026 provide growth catalysts, while competitive pressures and market volatility present risks. With a consensus price target of $103.64 offering 40% upside potential, the stock presents value for long-term investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
